Tonix Pharmaceuticals Holding Corp. (TNXP) Receives Average Recommendation of “Buy” from Brokerages
Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) have earned an average rating of “Buy” from the six analysts that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $8.33.
Several equities research analysts have commented on the company. ValuEngine downgraded Tonix Pharmaceuticals Holding Corp. from a “sell” rating to a “strong sell” rating in a report on Monday, October 2nd. Aegis assumed coverage on Tonix Pharmaceuticals Holding Corp. in a report on Monday, June 26th. They issued a “buy” rating and a $10.00 target price on the stock. Dawson James reissued a “buy” rating and issued a $9.00 target price on shares of Tonix Pharmaceuticals Holding Corp. in a report on Wednesday, August 23rd. Drexel Hamilton assumed coverage on Tonix Pharmaceuticals Holding Corp. in a report on Tuesday, August 22nd. They issued a “buy” rating on the stock. Finally, Roth Capital raised Tonix Pharmaceuticals Holding Corp. from a “neutral” rating to a “buy” rating and set a $6.00 target price on the stock in a report on Friday, August 18th. They noted that the move was a valuation call.
Tonix Pharmaceuticals Holding Corp. (TNXP) traded down 0.85% during midday trading on Thursday, reaching $4.67. The company had a trading volume of 49,476 shares. The company has a 50-day moving average of $4.19 and a 200-day moving average of $4.13. The stock’s market capitalization is $35.06 million. Tonix Pharmaceuticals Holding Corp. has a 12-month low of $2.85 and a 12-month high of $9.40.
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) last released its earnings results on Monday, August 14th. The company reported ($0.65) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.78) by $0.13. On average, analysts predict that Tonix Pharmaceuticals Holding Corp. will post ($3.02) EPS for the current fiscal year.
In related news, CEO Seth Lederman bought 20,000 shares of the company’s stock in a transaction on Thursday, August 17th. The shares were acquired at an average cost of $3.00 per share, with a total value of $60,000.00. Following the completion of the acquisition, the chief executive officer now owns 11,166 shares of the company’s stock, valued at approximately $33,498. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 4.00% of the company’s stock.
Several hedge funds have recently bought and sold shares of TNXP. B. Riley Financial Inc. purchased a new position in shares of Tonix Pharmaceuticals Holding Corp. in the second quarter worth $1,637,000. Vanguard Group Inc. raised its stake in shares of Tonix Pharmaceuticals Holding Corp. by 28.8% in the second quarter. Vanguard Group Inc. now owns 184,377 shares of the company’s stock worth $799,000 after purchasing an additional 41,264 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new position in shares of Tonix Pharmaceuticals Holding Corp. in the first quarter worth $119,000. Hedge funds and other institutional investors own 27.97% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/10/12/tonix-pharmaceuticals-holding-corp-tnxp-receives-average-recommendation-of-buy-from-brokerages.html.
Tonix Pharmaceuticals Holding Corp. Company Profile
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The companys lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.
Receive News & Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related companies with MarketBeat.com's FREE daily email newsletter.